We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

May 14, 2021

The Role of DiGA in your Go-to-Market strategy for Germany

Announcements/News
Meaghan Schedel
&

As more and more Digital Therapeutics (DTx) are developed, we are often asked: what are the most scalable and sustainable routes to market? The right commercialization model is a key component of success in this rapidly growing space. However, whether you choose a pharma partnership or another popular distribution channel, success is likely to depend on physician awareness of your DTx and their willingness to prescribe it. A direct-to-consumer approach is one way around this, but it too has its own advantages and disadvantages.

Germany’s DiGA, also known as Digital Health Applications or Digitale Gesundheitsanwendungen in German, and similar DTx review platforms (like the mhealth pyramid in Belgium) have the potential to play a key role in not only providing a path to reimbursement for DTx, but also for increasing provider awareness and trust in digital therapies. Apps that are approved for the DiGA database become reimbursable under the German statutory health insurance, making them prescribable to approximately 72.8 million people, 87.7% of the German population.


Facts and Figures: Approvals, pricing, and more 


Approvals 


Since the launch of the DiGA in 2019 as part of Germany’s initiative to increase the digitization of healthcare, the German Federal Institute for Drugs and Medical Devices (BfArM) has received a total of 72 DiGA submissions (updated: May 12th, 2021). So far 15 of these submissions have been approved and added to the DiGA Directory, 3 were denied, 30 were withdrawn, and 24 are still under review. The DiGA’s fast-tracked review process is designed to provide a rapid review of applications guaranteeing a positive or negative designation within three months or less. 


CE-marked medical devices are eligible to apply for the DiGA database so long as

1) They are a medical device of risk class I or IIA;

2) Their main function is based on digital technologies;

3) The medical purpose is achieved through the apps main digital functions;

4) The DiGA detects, monitors, treats or alleviates a disease or compensation of injuries or disabilities;

5) And finally, the DiGA must be used only by the patient or by the patient and physician in combination. 


Application process and review  


Once the application is submitted, DiGA applicants are assessed based on criteria such as data security, user friendliness, and interoperability. All DiGA must also be able to demonstrate a “positive healthcare effect” during the application process or following a 1-2 year trial phase in order to receive final admission into the database. 


A Positive Healthcare Effect


With only 15 approved applications to date, most new submissions will have to demonstrate the benefits of their app as compared to the “standard of care.” However, as the database becomes more crowded and DiGA approved applications become part of the new standard of care, applicants may be required to demonstrate how their app holds up to the competition. In these cases it will become increasingly important for apps to clearly define how their USP differs from that of an already approved DiGA with a similar value proposition. Price becomes a determining factor in a situation where two or more DiGA approved apps are determined to be no different from one another. In this case the physician may be required to prescribe the more cost-efficient option. 


Pricing 


Kalmeda is currently the least expensive app on the database at 116,97 Euros and Elevida is the most expensive at  743,75 Euros. The prescription length for these apps and most others is 90 days. With only a few apps on the database so far, it will be interesting to see how prices change as the marketplace becomes more crowded. Brian Dolan at Exits & Outcomes is tracking the latest additions to the DiGA as well as temporarily added products that may later be removed by the BfArM if they don’t receive final approval. 

Current DiGA Apps 


Approved applications cover a variety of conditions such as cancer, multiple sclerosis, and after care for stroke victims. However, many of the 15 approved apps address mental health and behavioral change. Julia Hagen, Director Regulatory & Politics at the Health Innovation Hub (hih) in Berlin, commented for MobiHealthNews, sharing that the initial focus on mental health applications is likely due to the vast number of available apps and evidence showing effectiveness in this space. She further stated: “There are also applications from completely different areas. Looking at the ongoing discussion and applications that are in the pipeline, we will soon see many other DiGA for various indications.”


Approved Apps 

Invirto - enables people with agoraphobia, panic disorder, or social phobia to receive home treatment for their anxiety disorder. 


Velibra - a web-based program for patients with generalized anxiety disorder, panic disorder with or without agoraphobia, or social anxiety disorder.  


Mindable - aims to treat adults 18 and over who suffer from the symptoms of agoraphobia and / or panic disorder. 


Kalmeda - a behavioral therapy for adults suffering from chronic ringing in the ears. 


Somnio - a digital application for the treatment of problems falling asleep and staying asleep (insomnia). 


ViViRA - a digital application for the treatment of back, knee, and hip pain. 


Zanadio - aims to help users reduce their weight by changing their exercise, nutrition, and other behavioral habits.


Elevida - designed for adults with multiple sclerosis who also have fatigue. 


M-sense Migraine - offers a comprehensive digital treatment program for migraine patients.  


Rehappy - supports aftercare for stroke patients. 


Selfapy - offers people with depression an individual online course based on evidence-based theories and techniques of cognitive behavioral therapy. 


deprexis - an interactive online-based self-help program that provides therapy support for adult patients with depression and depressive moods. 


CANKADO - a web and app based digital application that supports breast cancer patients.  


Mika - designed to support the alleviation of psychological and psychosomatic consequences of cancer diagnosis and therapy. 


Vorv!da - designed for adult patients with harmful alcohol consumption or alcohol dependence.

Physician Awareness and Trust 

It is also yet to be seen how strongly physicians will value DiGA approval and if this will increase their willingness to prescribe digital therapies to patients. So far approved DiGA apps have not seen a large increase in prescriptions as a result of their DiGA designation. In a study of 51 general practitioners conducted between April and May of 2020 and published by the Deutsches Ärzteblatt, an official journal of the German Medical Association and the National Association of Statutory Health Insurance Physician, 63% of practitioners polled described their willingness to prescribe DiGA as low or mostly low and 37% of practitioners reported their willingness as high or rather high. Our HealthXL insights show physicians are also concerned they won’t be able to answer technical questions about the apps and that it may take significant time to educate patients. As is the case for all emerging digital therapeutics, more education will be needed to increase patient and physician awareness of these new technologies and how they can be beneficial. 


However, a DiGA designation may provide a stamp of approval that increases both provider trust and awareness. Unlike a drug, a DTx may continue to change and evolve once it's on the market. For example, a DTx that uses a machine learning algorithm will continue to adapt as more user information becomes available. While this is likely positive for the app and ultimately for the patient, the potential that there may be changes to the DTx that the physician is not aware of can decrease the chance that a physician will prescribe the application. 


The DiGA has the potential to provide a sense of security and act as a time saver for physicians who want confirmation the app hasn’t undergone any significant changes without having to re-research the product before writing each prescription. The DiGA requires apps to report any “significant change.” According to criteria outlined by the BfArM this would not include something like an update to the design of a DiGA, but it would include changes to information published in the directory (such as price), changes to the safety or quality of the device, any changes to the application’s ability to meet DiGA requirements, changes to data protection, and any changes to the proof of positive healthcare effects. This requirement for DiGA to self-report changes or otherwise risk being removed from the database, may help build provider trust in the list of applications available on the database. 


The DiGA database and others like it could be an extremely valuable tool for physician education and awareness. While the early stages haven’t shown a large uptake in prescriptions, it is likely that as DTx continue to grow in range, capability, and popularity, patients will soon be asking their physicians about these alternative treatments and physicians will need a trusted source to consult. 


As this tide begins to turn, it is likely DiGA status will be a crucial component of success in the German market as well as other European markets that are following Germany’s lead. In addition to Belgium’s mhealth pyramid, we are also seeing mhealth and electronic EHR initiatives out of France, Norway, and Italy. The COVID-19 pandemic demanded innovation and acceptance of digital therapies and virtual care. Following the pandemic, we expect to see continued growth in these areas across Europe and the world. 


To learn more about other routes to market check out our “Best routes to market” meeting on May 31st featuring Louis Payet and Todd Greenwood.

Sources: 


https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Broschueren/200629_BMG_Das_deutsche_Gesundheitssystem_EN.pdf


https://www.bfarm.de/EN/MedicalDevices/DiGA/_node.html


https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.pdf?__blob=publicationFile&v=2 (p. 26 & 83) 


https://www.healthcareitnews.com/news/emea/european-digital-health-revolution-wake-covid-19 


https://www.mobihealthnews.com/news/emea/germany-approves-new-digital-mental-health-app-prescription 


https://www.digitalhealthglobal.com/italy-eyes-digital-therapeutics/



https://www.aerzteblatt.de/archiv/217790/Digitale-Gesundheitsanwendungen-Die-Akzeptanz-steigern 


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Sprint: Prescription DTx - Commercialization Models & Adoption

21st September @ 10:45AM EDT

Join this series of 2 meetings to discuss with other senior leaders Commercialization Models & Adoption in Prescription DTx. Limited spaces available so apply now to secure your place in the conversation.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wire Ventures
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wire Ventures
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Medtech partnerships

23rd September @ 10:45AM EDT

Join us in this informal conversation with senior leaders how DTx companies should think about Medtech as the appropriate partner and vice versa. Apply now to connect with peers and network with new people.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Sean Cheng
Sean Cheng
VC Investor, Philips Ventures
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Sean Cheng
Sean Cheng
VC Investor, Philips Ventures
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx in Mental Health: Scaling access to care - Fireside chat with Big Health Co-founder & CEO Peter Hames

23rd September @ 10:00AM EDT

Do you want to learn from one of the top DTx companies in mental health? Join us in this exclusive fireside chat with Peter Hames, co-Founder and CEO at Big Health, where we will talk about the early days of DTx in mental health, Big Health’s differentiated commercialization models, industry leading clinical evidence and the significant opportunity to address the mental health crisis by expanding access to mental health care.

Featuring
Peter Hames
Peter Hames
Co-Founder & CEO of Big Health
Martin Kelly
Martin Kelly
Co-founder & CEO, HealthXL
Featuring
Peter Hames
Peter Hames
Co-Founder & CEO of Big Health
Martin Kelly
Martin Kelly
Co-founder & CEO, HealthXL
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Sprint: DTx for Mental Health

28th September @ 10:45AM EDT

This series of 2 meetings to discuss in detail with other senior leaders the current state of DTx in mental health, what indications are best suited to such interventions, and commercial opportunities that they present.  Perfect opportunity to listen, engage and enjoy.

Featuring
Krys Zaluski
Krys Zaluski
Director Of Business Development - Digital Health at Sunovion Pharmaceuticals
Francesca Wuttke
Francesca Wuttke
Chief Digital Officer, Almirall
Featuring
Krys Zaluski
Krys Zaluski
Director Of Business Development - Digital Health at Sunovion Pharmaceuticals
Francesca Wuttke
Francesca Wuttke
Chief Digital Officer, Almirall

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Sprint: Prescription DTx - Commercialization Models & Adoption

21st September @ 10:45AM EDT

Join this series of 2 meetings to discuss with other senior leaders Commercialization Models & Adoption in Prescription DTx. Limited spaces available so apply now to secure your place in the conversation.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wire Ventures
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wire Ventures
Michael Pace
Michael Pace
Founder and President at PalmHealth.co
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Commercialization models for Virtual Care in Cardiometabolic Diseases

21st September @ 9:45AM EDT

Join us as we discuss commercialization models for Virtual Care in Cardiometabolic Diseases. Our 75 minute sessions are highly interactive and give attendees the opportunity to hear from senior leaders in the space and also share their own thoughts on the topic

Featuring
Shahram Sharif
Shahram Sharif
Board Director, LindaCare
Abhishek Shah
Abhishek Shah
CEO, Wellthy Therapeutics
Featuring
Shahram Sharif
Shahram Sharif
Board Director, LindaCare
Abhishek Shah
Abhishek Shah
CEO, Wellthy Therapeutics
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Medtech partnerships

23rd September @ 10:45AM EDT

Join us in this informal conversation with senior leaders how DTx companies should think about Medtech as the appropriate partner and vice versa. Apply now to connect with peers and network with new people.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Sean Cheng
Sean Cheng
VC Investor, Philips Ventures
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Sean Cheng
Sean Cheng
VC Investor, Philips Ventures
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx in Mental Health: Scaling access to care - Fireside chat with Big Health Co-founder & CEO Peter Hames

23rd September @ 10:00AM EDT

Do you want to learn from one of the top DTx companies in mental health? Join us in this exclusive fireside chat with Peter Hames, co-Founder and CEO at Big Health, where we will talk about the early days of DTx in mental health, Big Health’s differentiated commercialization models, industry leading clinical evidence and the significant opportunity to address the mental health crisis by expanding access to mental health care.

Featuring
Peter Hames
Peter Hames
Co-Founder & CEO of Big Health
Martin Kelly
Martin Kelly
Co-founder & CEO, HealthXL
Featuring
Peter Hames
Peter Hames
Co-Founder & CEO of Big Health
Martin Kelly
Martin Kelly
Co-founder & CEO, HealthXL

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.